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ABSTRACT: The HIV-1 nucleocapsid (NC) protein represents an excellent molecular target for the development of anti-
retrovirals by virtue of its well-characterized chaperone activities, which play pivotal roles in essential steps of the viral life cycle.
Our ongoing search for candidates able to impair NC binding/annealing activities led to the identiﬁcation of peptidyl-
anthraquinones as a promising class of nucleic acid ligands. Seeking to elucidate the inhibition determinants and increase the
potency of this class of compounds, we have now explored the eﬀects of chirality in the linker connecting the planar nucleus to
the basic side chains. We show here that the non-natural linker conﬁguration imparted unexpected TAR RNA targeting
properties to the 2,6-peptidyl-anthraquinones and signiﬁcantly enhanced their potency. Even if the new compounds were able to
interact directly with the NC protein, they manifested a consistently higher aﬃnity for the TAR RNA substrate and their TAR-
binding properties mirrored their ability to interfere with NC-TAR interactions. Based on these ﬁndings, we propose that the
viral Tat protein, sharing the same RNA substrate but acting in distinct phases of the viral life cycle, constitutes an additional
druggable target for this class of peptidyl-anthraquinones. The inhibition of Tat-TAR interaction for the test compounds
correlated again with their TAR-binding properties, while simultaneously failing to demonstrate any direct Tat-binding
capabilities. These considerations highlighted the importance of TAR RNA in the elucidation of their inhibition mechanism,
rather than direct protein inhibition. We have therefore identiﬁed anti-TAR compounds with dual in vitro inhibitory activity on
diﬀerent viral proteins, demonstrating that it is possible to develop multitarget compounds capable of interfering with processes
mediated by the interactions of this essential RNA domain of HIV-1 genome with NC and Tat proteins.
■ INTRODUCTION
Current anti-HIV therapeutics tend to exhibit desirable potency
and selectivity, as well as undesirable clinical limitations, which
stem from putative toxic eﬀects associated with long-term
treatments and the relentless emergence of resistant strains. As
a consequence, there is an urgent need to develop new
therapeutic agents against essential viral determinants that are
not currently targeted by available drugs.1−3 The HIV-1
nucleocapsid (NC) protein represents an attractive and
promising target by virtue of its highly conserved nature
among viral clades and its vital roles in a range of processes of
the viral lifecycle.4 This relatively small, basic protein is
characterized by two CCHC-type zinc-ﬁnger domains that are
highly conserved and confer the ability to directly interact with
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viral nucleic acids and to catalyze essential structural rearrange-
ments.4 In particular, its interaction with susceptible substrates
can induce transient melting of base-pairing, which makes
previously paired strands available for reannealing in diﬀerent
patterns conducive to more thermodynamically stable con-
formations.5−10 An example of this activity is provided by the
rearrangement of the transactivation responsive element
(TAR), an essential domain of the viral genome, which is
characterized by a relatively stable bulge−loop structure (Figure
1). Annealing of TAR RNA to a reverse-transcribed
complementary DNA (cTAR, Figure 1) is an obligatory step
of the reverse transcription process of viral genome. This
operation is mediated by NC, which is responsible for melting
the secondary structures of TAR and cTAR and promoting the
formation of the more stable heteroduplex TAR/cTAR (Figure
1), thus allowing for the minus strand-transfer and reverse
transcription processes to proceed.11
These essential chaperone properties make NC a potential
target for ligands capable of either preventing its interaction
with the target substrate or stabilizing the substrate structure to
forestall the expected rearrangements. Based on this hypothesis,
we identiﬁed 2,6-dipeptidyl anthraquinones (2,6-AQ) as a class
of potent anti-NC agents in vitro.12−14 The chemical structure
of these compounds is characterized by an anthraquinone
nucleus bearing aminoacyl linkers at positions 2 and 6, which
connect to terminal anchor groups containing a set of diﬀerent
positively charged moieties (e.g., linear or cyclic alkyl chains, as
well as heterocyclic or aminophenyl chains, Figure 2). Acting as
threading intercalators, we proved that these compounds
interfere with NC activity by stabilizing the rather dynamic
structures of TAR and cTAR.12,13
A thorough structure−activity relationship (SAR) analysis of
related series of 2,6-dipeptidyl anthraquinones, which bore a
wide variety of aminoacyl linkers, identiﬁed key structural
requirements necessary for the development of putative NC
inhibitors.12,13 The studies underscored the importance of the
length of the highly basic terminal residues and the ﬂexibility of
the linear linkers connecting them to the aromatic nucleus to
achieve the desired binding and stabilization of the cognate
nucleic acid substrates. However, when we compared Gly and
L-Ala linkers in side chains of ﬁxed optimal length, we observed
a sizable loss of inhibitory activity in spite of their similar
nucleic acid binding and stabilizing properties. This observation
suggested that either the linker conﬁguration or the presence of
a branching methyl group in Ala could represent important
factors in determining inhibition.
In this report, we tested the signiﬁcance of linker chirality by
synthesizing a new complete series of 2,6-disubstituted
anthraquinones, which contained Ala linker residues in the
non-natural D conﬁguration (i.e., 2,6-AQ-D-Ala-X, D-4a-i,
Figure 2). We then evaluated their activity in vitro by
employing the same assays developed earlier to test the
analogous series with opposite linker conﬁguration (i.e., 2,6-
AQ-L-Ala-X, L-4a-i, Figure 2).12 This modus operandi enabled
direct comparisons with previously reported results, which
allowed us to detect the sometimes subtle eﬀects of chirality.
The experiments revealed unexpected properties that suggested
additional mechanisms of action for this class of compounds
and, based on these ﬁndings, pointed toward alternative
potential targets. The results were discussed in the context of
our SAR analysis of peptidyl-anthraquinones and used to glean
a possible outlook for the development of actual therapeutics
from these types of structures.
Figure 1. Constructs replicating TAR RNA (blue) and cTAR DNA
(green) employed in the study. The scheme describes a key step of the
reverse transcription of viral RNA, in which NC destabilizes these
stem-loop structures to promote their annealing into a stable TAR/
cTAR heteroduplex.
Figure 2. Newly synthesized 2,6-dipeptidyl anthraquinones considered in this study (i.e., 2,6-AQ-D-Ala-X, D-4a-i). For reference purposes, the
chemical structures of compounds investigated earlier are also provided (i.e., 2,6-AQ-L-Ala-X, L-4a-i).12
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■ CHEMISTRY
Synthesis of 2,6-AQ-D-Ala-X Anthraquinone Deriva-
tives. Compounds D-4a-i (Figure 2) were obtained according
to the synthetic strategy summarized in Scheme 1, which
included appropriate modiﬁcations of a previous procedure
reported for 2,6-disubstituted anthraquinones.12 Brieﬂy, the
general strategy is based on the condensation of the 2,6-
diaminoanthraquinone nucleus 1 with Fmoc-protected acyl
chloride 2 in the presence of pyridine in DMF. Each reaction
mixture was submitted to overnight stirring at room temper-
ature. The resulting material was then dried and treated with
33% diethylamine in THF to remove the Fmoc protecting
group. The material was successively reacted with triﬂuoro-
acetic acid in H2O (9:1; v/v) to obtain intermediate 3, which
was in turn coupled with the protected amino acid of choice in
the presence of HBTU and DMAP in DMF. The Fmoc and
Boc protecting groups were removed by using 33% diethyl-
amine in THF and triﬂuoroacetic acid in H2O (9:1; v/v),
respectively, to produce the desired compounds 4a−i.
Fmoc-D-Ala-Cl (2) was prepared from commercially available
Fmoc-D-Ala-OH, which was treated with an excess of thionyl
chloride in CH2Cl2, and then heated by microwave irradiation
in a sealed vessel for 8 min (Scheme 2). We found that
increasing temperature, reaction time, or microwave power did
not increase the product yield, but rather induced reagent
decomposition.
The ﬁnal compounds were puriﬁed by preparative RP-HPLC
and fully characterized by mass spectrometry, 1H NMR, and
13C NMR. The data recorded for all ﬁnal compounds were
consistent with their proposed structures.
■ RESULTS AND DISCUSSION
Eﬀects of 2,6-Dipeptidyl Anthraquinones on NC-
Mediated Melting of Individual TAR and cTAR
Structures. The eﬀects of the new series of 2,6-AQ-D-Ala-X
derivatives (D-4a-i in Figure 2) on the NC-induced
destabilization of individual TAR and cTAR structures were
evaluated by using an adaptation of a high throughput
screening (HTS) approach described earlier.12−15 Brieﬂy, the
assay employed nucleic acid substrates consisting of 29-mer
constructs that replicated the apical portion of the TAR domain
of viral RNA and its complementary DNA sequence (i.e., TAR
and cTAR, Figure 1). The 5′ and 3′-ends of each construct
were appropriately labeled with either a ﬂuorophore or a
quencher, which enabled the determination of the stem-melting
activity of NC from the observed ﬂuorescence emission. In
particular, the emission recorded in the absence of ligand
provided a measure of the baseline activity of NC, which
minimized quenching by dissociating the double-stranded stem
and increasing the distance between ﬂuorophore and quencher.
In the presence of ligand, instead, decreasing ﬂuorescent
emission was caused by inhibition of the NC’s melting activity,
which left a higher proportion of substrate in the stem-loop
form conducive to quenching.12,13,16 In addition to initial
Scheme 1. General Synthetic Pathway for the Preparation of the Anthraquinone Derivatives Included in the Studya
aReagents and conditions: (i) Pyridine, DMF; (ii) 33% Diethylamine, THF; (iii) TFA/H2O; (iv) HBTU, DMAP, DMF; (v) 33% Diethylamine,
THF; (vi) TFA/H2O.
Scheme 2. Preparation of Intermediate 2
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baseline determinations, control experiments were also carried
out to ensure that the compounds of interest were incapable of
inducing direct quenching in the absence of NC (see
Experimental Section). A series of determinations were
completed with increasing amounts of ligand to determine
the concentration that induced 50% reduction of the baseline
activity (expressed as IC50).
12−14,16
The data obtained from the D-4a-i anthraquinones revealed
that derivatives bearing doubly charged linear-alkyl side chains
possessed potent inhibitory properties (e.g., D-4e-h in Table
1). In particular, the lowest IC50 values were exhibited in both
TAR and cTAR determinations by the D-4g and D-4h
compounds, with the latter providing 3.35 and 2.16 μM on
the respective assay. Compound D-4b with a monocharged
cyclic alkyl side chain showed somewhat intermediate potency
with preferential activity on TAR, whereas all other compounds
bearing cyclic aliphatic or aromatic moieties displayed lower
potency. A close examination of these results suggested that
increasing the length of the linear side-chain may increase the
potency according to a D-4h > D-4g > D-4f > D-4e relative
scale, which agreed with the results of our previous SAR study
on compounds with either Gly or L-Ala linkers.12,13
A direct comparison between corresponding IC50 values
observed for the analogous 2,6-AQ-D-Ala-X and 2,6-AQ-L-Ala-
X12 series (Figure 3) revealed that compounds bearing linear
terminal alkyl residues (i.e., 4d−h) were generally more potent
when the linker was in the non-natural D-conﬁguration rather
than their L-conﬁguration counterparts. This was remarkable in
particular when TAR was assayed rather than cTAR (Figure S1
in Supporting Information). 2,6-AQ-D-Ala-X compounds
bearing cyclic or heterocyclic side chains (4a, 4c, and 4i)
displayed in all cases weaker activity than the corresponding L-
Ala-X counterparts, with the exception of the aminomethyl-
cyclohexyl D-4b, whose behavior on TAR in this assay clusters
within the ﬂexible linear-alkyl category. These diﬀerences
between the activity of the L-Ala and the D-Ala series of
compounds highlight the signiﬁcant impact of the stereo-
chemistry of the chiral amino acidic linker on the 2,6-dipeptidyl
anthraquinones structure−activity relationship, therefore an-
swering our initial question on the importance of the
conﬁguration of the connecting Ala moiety in NC inhibition.
Eﬀects of 2,6-Dipeptidyl Anthraquinones on NC-
Mediated Annealing of TAR and cTAR Constructs. The
nucleic acid chaperone activities of NC are substantiated by its
ability to destabilize double-stranded regions of RNA structure
and enable their reannealing into more stable pairing
arrangements. In the TAR/cTAR system, initial melting of
the intrastrand pairs that deﬁne their individual stem-loop
structures can lead to interstrand annealing with formation of a
stable TAR/cTAR heteroduplex.11,17 The ability to monitor
this process provided us with the opportunity to evaluate the
eﬀects of the 2,6-AQ-D-Ala-X anthraquinones on the annealing
activity of NC in vitro. We employed the nucleocapsid
annealing mediated electrophoresis (NAME) assay described
earlier,12,18 which was carried out according to alternative
protocols involving preincubation of ligand with either the NC
protein or the nucleic acid substrates (see Experimental
Section). Our tests revealed that only compounds D-4e-h
possessed detectable inhibitory activity in these experiments
(see Figure S2 of Supporting Information). Furthermore, D-Ala
compounds were more active upon nucleic acid preincubation,
in analogy with previous observations obtained from other
series of peptidyl anthraquinones.12,18 Tests were repeated
using a wider range of ligand concentrations to obtain IC50
values as a measure of their ability to interfere with annealing
activity under the selected experimental conditions (see
representative gel for D-4h in Figure S3 of Supporting
Information and Table 2).
The results showed that linear anthraquinones D-4e-h
possessed inhibitory activities consistent with a D-4h > D-4g
> D-4f ≈ D-4e relative scale of potency. Not surprisingly, this
Table 1. Inhibition of NC-Mediated Melting of Individual
TAR and cTAR Structures
Compound IC50 TAR
a (μM) IC50 cTAR
a (μM)
D-4a 39.7 ± 3.99 24.9 ± 2.20
D-4b 8.79 ± 0.11 12.8 ± 1.09
D-4c 51.3 ± 5.01 32.1 ± 2.76
D-4d 33.7 ± 2.05 19.9 ± 1.58
D-4e 10.5 ± 1.50 13.8 ± 1.50
D-4f 9.24 ± 0.49 6.52 ± 0.47
D-4g 3.27 ± 0.44 4.76 ± 0.68
D-4h 3.35 ± 0.51 2.16 ± 0.37
D-4i 47.4 ± 1.34 20.2 ± 0.78
aValues are the mean of data obtained from three experiments, each
performed in triplicate.
Figure 3. IC50 values observed for the eﬀects of 2,6-AQ-D-Ala-X
(purple, this study) and 2,6-AQ-L-Ala-X (yellow, ref 12) compounds
on the NC-induced helix destabilization of TAR structure (see
Experimental Section).
Table 2. Inhibition of NC-Mediated Annealing of TAR/
cTAR Assessed by NAME Assay
compound IC50 NAME
a (μM)
D-4a >100
D-4b >100
D-4c >100
D-4d >100
D-4e 76.7 ± 8.61
D-4f 78.8 ± 10.8
D-4g 37.5 ± 13.6
D-4h 28.9 ± 4.59
D-4i >100
aValues represent the mean and standard error of the mean (SEM)
obtained from experiments performed in triplicate.
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scale matched that observed for the potency of inhibition of
NC-induced melting of TAR and cTAR, which was also
correlated with the length of the doubly charged side chain.
Compound D-4h was the most potent inhibitor of both
melting and annealing activities with respective IC50s of 3.35
and 28.9 μM (Tables 1 and 2). This was not the case for its 2,6-
AQ-L-Ala-X analog L-4h, which was signiﬁcantly less active
both in the melting and in the annealing assay (i.e., IC50 of 6.61
and 80.4 μM).12 The outcome of these experiments further
indicates that the non-natural D conﬁguration of Ala-linkers is a
strong inhibition determinant of 2,6-dipeptidyl-anthraquinone
compounds.
Binding Modes of 2,6-Dipeptidyl Anthraquinones to
Individual TAR and cTAR Structures. In the formerly
analyzed L-Ala linker series, the NC inhibitory properties
mirrored their nucleic acid binding capabilities, providing
strong evidence that the mechanism of action involve
stabilization of TAR and cTAR secondary structure through
intercalation of their anthraquinone systems.12,13 With the new
D-Ala series, we therefore evaluated the eﬀects of varying the
linker conﬁguration on the binding features on TAR and cTAR,
employing electrospray ionization mass spectrometry (ESI-MS)
analysis under nondenaturing conditions as performed for the
L-Ala series (see Experimental Section).12,13,19−21
Initial determinations were carried out in the absence of
ligand to verify the experimental masses of the TAR and cTAR
constructs, which matched very closely those calculated from
the respective sequences (i.e., 9286.2 u experimental versus
9286.3 Da monoisotopic mass calculated for TAR; 8884.5 u
versus 8884.5 Da for cTAR). Subsequent analyses were
conducted on sample solutions that contained, respectively, 1
and 10 μM concentrations of nucleic acid substrate and 2,6-
dipeptidyl anthraquinone ligand (i.e., a 1:10 molar ratio).
Representative ESI-MS spectra obtained from mixtures of D-4h
with either TAR or cTAR are provided in Figure 4, which
displays only the regions containing the 6- or 5-charge state for
the sake of clarity. Experimental and calculated monoisotopic
masses for all the detected species are provided in Tables S1
and S2 of Supporting Information.
Consistent with the ability of ESI-MS to observe intact
noncovalent complexes between nucleic acids and peptidyl-
anthraquinones,12,14 all spectra contained signals corresponding
to free unbound substrates, as well as stable complexes with
diﬀerent stoichiometries. The observed binding patterns did
not reveal signiﬁcant cooperativity for either substrate (Figures
4 and S4). In all cases, the coexistence of free TAR or cTAR
with complexes of diﬀerent stoichiometries indicated that
binding to the second site was initiated before saturation of the
ﬁrst was complete, consistent with the presence of independent
binding sites with equivalent aﬃnities on either construct. The
results revealed a clear correlation between binding stoichiom-
etry and the inhibition of annealing activity revealed by the
NAME assays. In particular, the D-4g and D-4h compounds,
which possessed the most pronounced inhibitory properties,
produced TAR complexes containing up to 3 and 4 equiv of
ligand, respectively. By contrast, the D-4b compound with the
least pronounced inhibitory properties produced only 1:1
complexes with TAR under the same experimental conditions.
In the case of the cTAR substrate, D-4g and D-4h produced
complexes with up to 4:1 stoichiometries, whereas D-4b
produced again only 1:1 complexes.
These results are quite consistent with what was previously
reported for the L-Ala series. We then proceeded to calculate
the relative binding aﬃnities of the various compounds for the
diﬀerent substrates, employing the percentage of bound
substrate observed in each spectrum (see Experimental
Section).12 The representative histograms in Figure 4C
revealed that D-4g and D-4h possessed comparable aﬃnities
that were much greater than those aﬀorded by D-4b under the
same experimental conditions (i.e., D-4g ≈ D-4h ≫ D-4b
relative scale). Surprisingly, D-4g and D-4h displayed a slightly
greater aﬃnity for the RNA than for the DNA substrate, which
contrasted with the behavior manifested by the corresponding
L-series analogues. In fact, the histograms obtained from the
data generated in our previous studies12,13 clearly demonstrated
that analogous compounds with L-Ala linker (named L-4g, L-
4h, and L-4a) possessed greater aﬃnities for cTAR than for
TAR (Figure S5 of Supporting Information).
The unexpected but detectable selectivity for the RNA rather
than for the DNA construct manifested by the D-analogues had
never been observed before and suggested further investigation.
We evaluated under the same experimental conditions the
binding properties of the strong TAR binder D-4h and its L-
counterpart L-4h to diﬀerent RNA substrates. We selected the
Figure 4. Representative ESI-MS spectra of samples containing a 1:10
molar ratio of either TAR (A) or cTAR (B) and D-4h (red ●)
compound in 150 mM ammonium acetate (see Experimental Section).
Symbol ■ corresponds to TAR RNA substrate and □ to cTAR DNA
substrate. The stoichiometries of the observed complexes are indicated
in each spectrum. Signals of lower intensity detected near free/bound
species consist of typical sodium and ammonium adducts. (C)
Histograms displaying the percentages of bound substrate observed in
A and B spectra and from Figure S4 for D-4b and D-4h. The indicated
percentages of bound substrate provide a measure of the relative
aﬃnities of D-analogues for either nucleic acid substrate.
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stem-loop SL3 sequence, a RNA domain of the HIV-1 genome
packaging signal, owing to the presence of an apical loop,19,20,22
and a random 16-mer double-stranded RNA (dsRNA)
sequence. As performed in the presence of TAR, ESI-MS
analyses were conducted on sample solutions that contained,
respectively, 1 and 10 μM concentrations of nucleic acid
substrate and 2,6-dipeptidyl anthraquinone ligand (not shown).
We calculated the relative binding aﬃnities of the compounds
for the diﬀerent substrates, employing the percentage of bound
substrate observed in each spectrum (see Experimental
Section). The representative histograms in Figure S6 (see
Supporting Information) compare the binding aﬃnities of
selected compounds for TAR (Figure 4C) with those observed
for SL3 and for the dsRNA. Once again the D-analogue
displayed a slightly greater aﬃnity for all the three RNA
substrates compared to its L-counterpart, corroborating our
hypothesis that the non-natural conformation of the linker in
the side chains is important to achieve RNA binding.
Noteworthy, the data clearly revealed that the test compounds
possess a remarkable greater binding aﬃnities for the bulge-
loop TAR structure than for both the stem-loop SL3 sequence
and the double-stranded RNA, highlighting their preferential
binding to dynamic bulged regions of RNA structures.
The increased selectivity toward TAR induced by the D-Ala
linker series suggests a possible strategy for designing RNA-
speciﬁc ligands, which deserves further investigation. In
addition, it entails the potential inhibition of other factors
that interact with this region of viral genome during the HIV-1
lifecycle, as we will discuss in the ﬁnal paragraph.
Multifaceted Aspects of 2,6-Dipeptidyl Anthraqui-
none Inhibition. Although the results obtained to this point
revealed excellent correlation between eﬃcient inhibition of
NC-mediated reactions and nucleic acid binding, they do not
satisfactorily explain the discrepancy between the diﬀerent
potencies in NC inhibition by the D- and L-Ala series. For this
reason, we tested whether direct binding to NC protein by 2,6-
AQ-D-Ala-X ligands could account for additional inhibitory
eﬀects. The experiments were carried out by comparing
samples that contained full-length NC and selected analogues
of the D- or L-series (see Experimental Section). Also in this
case, ESI-MS analyses were carried out under nondenaturing
conditions to enable the detection of intact complexes with
fully metalated NC (see Experimental Section).23 Control
experiments in the absence of ligand aﬀorded a mass of 6489.1
u, which matched very closely the monoisotopic value of 6488.9
Da calculated from the sequence and including two Zn(II) ions.
Representative spectra obtained in the presence of selected 2,6-
AQ-D-Ala-X anthraquinones are shown in Figure 5, while those
obtained in the presence of their 2,6-AQ-L-Ala-X counterparts
are reported in Figure S7 (Supporting Information). For the
sake of clarity, only the regions corresponding to the 4+ charge
states were plotted on the same intensity scale to enable a
direct comparison of the abundances of the respective
complexes. Observed and expected masses for all the detected
species are reported in Table S3 (Supporting Information).
The results clearly showed that the ligands were capable of
binding to full-length NC to form stable 1:1 complexes, with
those containing compound D-4g and D-4h displaying greater
abundances than those containing D-4b.19,24 The masses
observed for these complexes were consistent with the presence
of two Zn(II) ions, which demonstrated that ligand binding did
not interfere at all with metal coordination (Table S3). The fact
that these species were detected with the same charge state
allowed us to estimate the partitioning between unbound and
bound species in the sample from their respective signal
intensities (see Experimental Section).19,24 This treatment
revealed that D-4g and D-4h produced fractional occupancies
of 14.4 ± 0.93 and 15.2 ± 0.60, respectively, whereas D-4b
provided only 3.57 ± 0.08. Under the same conditions, the
corresponding L-4g and L-4h (L-Ala linker series) analogues
aﬀorded occupancy values of 13.3 ± 0.60 and 6.14 ± 0.79,
which were decidedly lower (Figure 5C). The relative
abundances observed for the complexes of NC with D-Ala
and L-Ala compounds (Figures 5 and S5, respectively) provided
a putative D-4h > D-4g > L-4g > L-4h relative scale of binding
aﬃnities for NC protein, which accurately matched the ranking
of the IC50s for annealing inhibition provided by the NAME
assays (see Table 2 and ref 12). The fact that corresponding D-
Ala and L-Ala analogues were consistently at the opposite ends
of these putative scales suggested direct correlations between
linker stereochemistry and NC binding, leading to enhanced
inhibitory activities.
Inhibition of the NC Binding to TAR by 2,6-Dipeptidyl
Anthraquinones. NC is a TAR binding protein: the ability of
selected 2,6-dipeptidyl anthraquinones to bind directly to NC
or to TAR raises several possibilities on the mechanism of NC
inhibition by these ligands. To gain a greater understanding of
the mechanism of action of D-Ala derivatives, we evaluated
these scenarios in systematic fashion by analyzing samples in
which preformed (i) NC-TAR, (ii) ligand-NC, or (iii) ligand-
TAR complexes were challenged by addition of the remaining
component (Scheme 3). This set of binding experiments was
Figure 5. Representative ESI-MS spectra from samples containing full-
length NC and ligand D-4b (A), D-4g (B), and D-4h (C), each in
1:10 substrate to ligand ratio (see Experimental Section). Weaker
signals near the main peak are typical sodium and ammonium adducts.
Only the region containing the 4+ charge state of complexes is
reported for clarity. (D) Histograms comparing the fractional
occupancy of D-analogues obtained from the above spectra with that
of their L-counterparts obtained from the data in Figure S5
(Supporting Information).
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initially performed in the presence of the strongest NC and
TAR binder, D-4h. The outcome of the experiments was
determined by performing ESI-MS under the same conditions
employed previously to evaluate ligand binding, which enabled
the unambiguous identiﬁcation of all species present at
equilibrium in solution.
Data in Figure 6 were obtained from a sample corresponding
to case i in Scheme 3, which was prepared by incubating
equimolar amounts of NC and TAR (i.e., 6 μM concentration
of each) for 15 min, and then added of a 1:10 molar ratio of D-
4h ligand (i.e., ﬁnal 60 μM concentration). The signal observed
for the NC•TAR complex upon ligand addition in Figure 6 was
signiﬁcantly weaker than that obtained for the same species in a
control experiment carried out in the absence of ligand (data
not shown). At the same time, strong signals were detected for
the D-4h•TAR species formed by displacement of the initial
NC-TAR complex. It is clear that upon NC displacement the
ligand D-4h forms several D-4h•TAR complexes, with the
same stoichiometries found in Figure 4A. Interestingly, we
observe for the ﬁrst time the formation of ternary complexes
between NC protein, TAR RNA, and D-4h ligand at diﬀerent
stoichiometries, with the notable exception of the ternary
complex containing 4 ligand molecules. We can therefore
assume that at least one of the four ligand-TAR binding sites
competes with NC binding site to TAR.
In analogous fashion, we analyzed the outcome of experi-
ments obtained by treating preformed D-4h•NC complex with
TAR (case ii in Scheme 3); again, this led to the detection of
abundant D-4h•TAR formed by complex displacement. Finally,
treating preformed D-4h•TAR with NC (case iii in Scheme 3)
provided signals corresponding to the initial species, with
intensity matching that observed in control experiments in the
absence of NC. Taken together, these results revealed that D-
4h•TAR was the most favorable complex under each scenario,
consistent with the relatively higher aﬃnity of this ligand for the
TAR substrate.
This is true also for the other strong TAR-binder D-4g.
Figure 7 reports a representative histogram comparing the
results from samples of D-4h, D-4g and D-4b, a poor TAR
binder. The relative abundance of the NC•TAR complexes in
the various samples corresponding to case i in Scheme 3 was
utilized to compare the inhibition eﬀects manifested by the
ligands (see Experimental Section).
Scheme 3. Schematic Representation of the Experimental
Procedures Employed to Evaluate the Inhibition of NC
Binding to TAR by Selected Ligandsa
aThe red oval represents the ligand. (i) Displacement of NC•TAR
complex was analyzed by adding ligand to the preformed protein-RNA
complex; (ii) interaction of NC with TAR substrate was assayed after
preincubation of the protein with ligand; (iii) NC protein was added
to preformed TAR-ligand complexes.
Figure 6. ESI-MS spectrum of samples obtained by adding ligand D-4h to the preformed TAR•NC complex (case i in Scheme 3). Lower intensity
signals near free/bound species consist of typical sodium and ammonium adducts. Gray ▲ corresponds to NC protein; ■ to the TAR RNA
substrate; and red ● to the D-4h ligand. For the sake of clarity only the 6- and 7-charge states of the binary (RNA-ligand) and ternary (RNA-ligand-
protein) complexes are labeled in the spectrum.
Figure 7. Representative histogram comparing the percentage of NC
protein bound to TAR RNA (NC•TAR complexes) in the presence of
ligand D-4h with those of D-4g and D-4b. Data were obtained from
ESI-MS analyses of samples prepared following the procedure i, shown
in Scheme 3 (see Experimental Section).
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The relative scale of competition for NC displacement from
TAR observed for the test compounds was D-4h > D-4g≫ D-
4b, which precisely mirrored the ranking for annealing
inhibition provided by the NAME assays (Table 2 and ref
12), once more revealing the correlation between TAR binding
and NC-mediated annealing inhibition.
2,6-Dipeptidyl Anthraquinone Eﬀects on Tat-TAR
Interactions. The observed ability of 2,6-AQ-D-Ala-X
compounds to establish speciﬁc interactions with the TAR
structure suggested that these ligands might be capable of
interfering with other functions enacted by this domain in the
viral lifecycle. We tested this hypothesis by examining their
putative eﬀects on the speciﬁc binding interactions between
TAR RNA and a peptide mimicking the HIV-1 trans-activator
of transcription (Tat) factor. This protein can promote the
eﬃcient transcription of integrated proviral genome,25−28 as
well as support the annealing activities of NC during reverse
transcription, thus earning itself the deﬁnition of nucleic acids
annealer.29,30 For this reason, we evaluated the eﬀects of
selected D-Ala analogues on the formation of the Tat-TAR
complex by using a ﬂuorescence-quenching approach. The
assay relied on a TAR construct labeled with an appropriate
quencher and a short stretch (aa 48−57) of the Tat protein
corresponding to the RNA binding region,31,32 which was
instead labeled with a ﬂuorescent dye (see Experimental
Section).14,33,34 In this way, the formation of the binding
complex produced eﬀective quenching, whereas its ligand-
induced inhibition enabled the detection of ﬂuorescence
emission. As reported in Table 3, anthraquinones D-4e-h
bearing linear alkyl side-chains strongly inhibited the formation
of Tat-TAR complex with a potency ranking that matched that
of NC annealing inhibition, i.e., D-4h > D-4g > D-4f > D-4e. In
particular, the strongest Tat-TAR inhibitors were again the D-
4g and D-4h compounds, which were also the most active TAR
binders and NC inhibitors.
Inspired by the results obtained from the investigation of
NC, we tested the possibility that the ligands may be capable of
binding the Tat peptide, as observed for NC. Following the
same strategy, the experiments were carried out mixing Tat
with selected analogues of the D-series, and then analyzing the
samples by ESI-MS under nondenaturing conditions. The
results showed unambiguously that the test ligands were not
capable of binding directly to the Tat peptide (data not shown),
thus indicating that the ability of D-analogues to interfere with
the Tat-TAR complex was based exclusively on their TAR-
binding properties.
■ CONCLUSIONS
This study was prompted by an earlier observation that the
activity of 2,6-disubstituted anthraquinones signiﬁcantly
beneﬁted from replacing L-Ala with Gly residues in the linkers
between anthraquinone nucleus and charged side-chain
groups.12 We hypothesized that the methyl group of L-Ala or
its conﬁguration was responsible for decreasing the ability to
inhibit NC. To test this hypothesis we synthesized and analyzed
a series of 2,6-AQ-D-Ala-X compounds containing non-natural
D-Ala residues. The results demonstrated that this modiﬁcation
restored the inhibitory properties, with D-Ala compounds
displaying the same type of correlation with side-chain length
observed for the potent Gly analogues. Indeed, as the length of
the linear alkyl side-chain increased in the 2,6-AQ-D-Ala-X
series, inhibition increased according to a D-4h > D-4g > D-4f
> D-4e relative scale of potency. In all assays, D-4h proved to
be the most potent inhibitor of the series by achieving
inhibition of NC activities in vitro at concentrations
comparable to those observed in earlier studies for the most
promising hits of the 2,6-AQ-ß-Ala-Orn and 2,6-AQ-Gly-Lys
series.12
In addition to providing new insights into the structure−
activity relationships of 2,6-dipeptidyl anthraquinones, this
study gave us the opportunity to further investigate the putative
mechanism of action of this class of compounds. At ﬁrst sight,
the inhibitory properties of ligands acting as threading
intercalators could be ascribed to their marked binding to
both TAR and cTAR secondary structures. In contrast, the
detectable selectivity for the TAR substrate manifested by the
D-analogues was never observed before and highlighted the
importance of this RNA structure to elucidate the NC
inhibition mechanism. RNA-binding small molecules are an
important and highly challenging area of therapeutic research.
Several classes of RNA binders have been reported,35−48 but
many of them display nonspeciﬁcity in RNA binding.49 The
presence of D-Ala linker in 2,6-dipeptidyl anthraquinones
leading to RNA recognition and TAR selectivity therefore
constitutes a new possible strategy for the development of
RNA-speciﬁc ligands, which deserves further investigation.
Pursuing by NMR study and docking experiments the high-
resolution structural determination of ligand-RNA complexes
will be necessary to understand at the molecular level the steric
eﬀects introduced by the non-natural stereochemical conﬁg-
uration.
Although the compounds tested in the study demonstrated
the ability to interact directly with the NC protein, their
binding aﬃnities for the protein were consistently inferior to
those manifested by the same compounds for the TAR
construct. Indeed, the detection of ternary complexes
containing protein, RNA, and ligands was consistent with the
possible presence of distinct binding sites onto the TAR
structure. The exception is represented by D-4h, which might
share at least a putative binding site with the NC protein
(Figure 6). Considering that this compound was also the most
potent inhibitor in the series (Tables 1 and 2), it would be
tempting to attribute its enhanced activity to the contribution
of a putative competition mechanism.
Additionally, the TAR-binding agents displayed the same
potency scale observed for NC when tested with the Tat-TAR
system, while simultaneously failing to demonstrate any direct
Tat-binding capabilities. These considerations conﬁrmed that
the mechanism of 2,6-dipeptidyl anthraquinones is based on
their nucleic acid tropism, rather than protein inhibition. For
this reason, they should be more appropriately deﬁned as TAR-
targeted candidates capable of interfering with processes
mediated by the interactions of this essential domain of HIV-
1 genome with NC and Tat proteins. Since Tat and NC are
Table 3. Inhibition of Tat-TAR Complex Formation
compound Ki
a (μM)
D-4b 1.31 ± 0.18
D-4e 0.79 ± 0.18
D-4f 0.54 ± 0.08
D-4g 0.14 ± 0.01
D-4h 0.11 ± 0.01
aValues are the mean ± SEM of data obtained by three experiments
performed in triplicate.
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multifunctional auxiliary proteins of HIV-1, both acting through
interaction with the TAR sequence, we believe that agents
capable of interfering with those critical steps are expected to
block HIV-1 replication at multiple levels. Dual targeting
through the same RNA substrate opens the possibility to
consider D-Ala-peptidyl-anthraquinones as pleiotropic inhib-
itors, able to interfere not only with NC-mediated reactions
during reverse transcription, but also with the Tat mediated
processes. The concomitant inhibition of diﬀerent targets
within the same pathway would possibly increase the genetic
barrier required to gain resistance toward these putative drugs.
In the end, the absence of binding with the Tat protein
represented a glaring but important contrast with the observed
NC-binding properties. Although our results are a very small
sampling, the selectivity toward the NC protein could
constitute the basis for further developing the D-series as
“true” anti-NC compounds. In this direction, additional studies
are currently underway to evaluate the eﬀects of new terminal
residues to improve the direct interaction of 2,6-dipeptidyl
anthraquinones with the hydrophobic plateau of NC protein,
thus combining in the same molecules diﬀerent mechanisms
contributing to the overall NC inhibition.
■ EXPERIMENTAL SECTION
Materials and Methods. For compound synthesis,
puriﬁcation (preparative HPLC) and chemical characterization
(analytical HPLC, ESI-MS, and NMR) we used the same
procedures, conditions, reactants and reagents reported in our
previous paper.12 Microwave reactions were performed using a
microwave oven (ETHOS 1600, Milestone) especially designed
for organic synthesis.
TAR is the 29-mer RNA sequence 5′-GGCAGAUCUGAG-
CCUGGGAGCUCUCUGCC-3′ and cTAR is its DNA
complementary sequence 5′-GGCAGAGAGCTCCCAGGC-
TCAGATCTGCC-3′. SL3 is the 20-mer sequence 5′-GGAC-
UAGCGGAGGCUAGUCC-3′.22 Duplex construct dsRNA
was obtained by annealing the 16-mer complementary
sequences 5′-UAGGGGGAAGCUUGG-3′ and 5′-CCAA-
AGCUUCCCCCUA-3′. All RNA and DNA oligonucleotides
were purchased from Metabion International AG (Martinsried,
Germany). The full-length recombinant NC protein was
obtained in house as previously reported.20
(R)-(9H-Fluoren-9-yl)methyl 1-chloro-1-oxopropan-2-yl-
carbamate (2; Fmoc-D-Ala-Cl). Commercially available
Fmoc-D-Ala-OH (Aldrich, 2.5 g, 8.03 mmol) was dissolved in
anhydrous dichloromethane (40 mL) in a two-neck ﬂask.
Excess SOCl2 (5 mL; 68.54 mmol) was added dropwise. The
mixture was transferred into a sealed vessel and heated by
microwave irradiation at 50 °C (300W power) for 8 min (30 s
ramping step; 7 min and 30 s holding step). Solvent was
evaporated under reduced pressure and the residue was puriﬁed
by crystallization from n-hexane aﬀording 2.60 g of pure 2a as a
white solid. Yield: 98%.
N,N′-(9,10-Dioxo-9,10-dihydroanthracene-2,6-diyl)bis(2-
aminoacetamide)-bistriﬂuoroacetate (3). Fmoc-D-Ala-Cl (2a,
6,39 g, 19,4 mmol) and pyridine (1.27 mL, 15.8 mmol) were
slowly added to a solution of 2,6-diaminoanthraquinone (1, 350
mg, 1.94 mmol) in DMF (80 mL). The reaction mixture was
stirred at room temperature for 24 h. Solvent was removed by
reduced pressure distillation. The residue was puriﬁed by
crystallization from ethyl acetate, thus obtaining bis((9H-
ﬂuoren-9-yl)methyl) ((2R,2′R)-((9,10-dioxo-9,10-dihydroan-
thracene-2,6-diyl)bis(azanediyl))bis(1-oxopropane-2,1-diyl))-
dicarbamate (2,6-Fmoc-D-Ala-anthraquinone) as an orange
powder (1.47 g, 1.78 mmol, yield 92%), which was used in
the next step without any further puriﬁcation. This compound
was reacted with a 33% diethylamine solution in THF (60 mL)
for 2 h. Solvent was again distilled oﬀ under reduced pressure
and the residue was ﬁnally reacted with a solution of
triﬂuoroacetic acid in water (9:1, v/v, 20 mL) for 1 h. Reaction
mixture was then added with diethyl ether (60 mL). The
precipitate was collected by centrifugation and dried to obtain
862 mg of intermediate 3a as an intense orange solid. Yield
73% (overall). 1H NMR (DMSO-d6): δ 11.28 (bs, 2H), 8.49
(d, 2H), 8.30−8.20 (m, 8H), 8.06 (dd, 2H), 2.69 (d, 6H), 2.50
(m, 2H). 13C NMR (DMSO-d6): δ 181.2, 165.6, 143.6, 134.2,
128.4, 128.2, 123.4, 115.5, 49.4, 16.6. ESI-MS: 380.15 [M +
H]+; 191.18 [M + 2H]++.
N,N′-(2S,2′S)-1,1′-(9,10-dioxo-9,10-dihydroanthracene-
2,6-diyl )bis(azanediyl)-bis(1-oxopropane-2,1-diyl)-
dipiperidine-4-carboxamide-bis-triﬂuoroacetate (D-4a). In-
termediate 3a (250 mg, 0.42 mmol) was dissolved in dry DMF
(18.6 mL), and DMAP (545.56 mg, 3.24 mmol), 1-Fmoc-
piperidine-4-carboxylic acid (Fmoc-Inp-OH, 1.00 g, 3.20
mmol), and HBTU (1.36 g, 3.6 mmol) were added. The
resulting solution was stirred at room temperature for 24 h,
then poured into Et2O and centrifuged. The solid obtained was
washed with Et2O, and the ﬁnal product was dried in vacuo and
used in the next step without any further puriﬁcation. In order
to remove the Fmoc-protecting group, the solid obtained was
reacted with a 33% diethylamine solution in THF (30 mL) for
2 h, poured into Et2O, and centrifuged. The solid obtained was
washed with Et2O and water and then dried in vacuo.
Subsequently, the obtained solid was reacted with a solution
of triﬂuoroacetic acid in water (9:1, v/v, 20 mL) for 1 h and
then poured into Et2O. The resulting suspension was
centrifuged. The solid obtained was washed with Et2O and
dried in vacuo. Puriﬁcation by preparative RP-HPLC aﬀorded
the pure compound D-4a as an intense orange solid. Yield:
76%. Orange solid. K′ (HPLC): 5,5. 1H NMR (DMSO-d6, 400
MHz): δ 10.71 (s, 2H), 8.71 (t, 2H), 8.44 (bs, 4H), 8.33 (d,
2H), 8.14 (bs, 4H), 8.03 (dd, 2H), 4.37 (m, 2H), 3.24 (m, 4H),
2.84 (m, 4H), 1.83 (m, 4H), 1.68 (m, 4H), 1.31 (d, 6H). 13C
NMR (DMSO-d6, 400 MHz): δ 181.79, 172.07, 168.73, 144.89,
134.82, 129.04, 128.68, 124.11, 116.44, 51.90, 50.02, 40.59,
38.72, 28.68, 23.02, 18.31. ESI-MS: 603.3 [M + H]+; 302.1 [M
+ 2H]++.
(1R,1′R,4S,4′S)-N,N′-((2S,2′S)-1,1′-(9,10-dioxo-9,10-dihy-
d r o a n t h r a c e n e - 2 , 6 - d i y l ) - b i s ( a z a n e d i y l ) b i s -
(1oxopropane2,1diyl))bis(4(aminomethyl)cyclohexane-car-
boxamide)-bis-triﬂuoroacetate (D-4b). We followed the
synthetic procedures reported for D-4a, starting from
i n t e rmed i a t e 3 a a n d 4 - ( Fmo c - am i n ome t h y l ) -
cyclohexanecarboxylic acid (N-Fmoc-tranexamic acid). Yield:
65%. Orange solid. K′ (HPLC): 6.4. 1H NMR (DMSO-d6, 400
MHz): δ 10.69 (s, 2H), 8.47 (t, 2H), 8.18 (d, 2H), 8.16 (d,
2H), 8.05 (dd, 2H), 7.77 (bs, 6H), 4.36 (m, 2H), 2.85 (m, 4H),
2.64 (m, 2H), 1.76 (m, 2H), 1.67 (m, 8H), 1.31 (d, 6H), 0.88
(m, 8H). 13C NMR (DMSO-d6, 400 MHz): δ 182.02, 172.43,
171.83, 144.69, 135.03, 129.18, 128.52, 124.11, 116.41, 51.82,
43.97, 38.02, 35.67 29.66, 29.13, 17.95. ESI-MS: 659.1 [M +
H]+; 330.2 [M + 2H]++.
N,N′-(1,1′-(9,10-Dioxo-9,10-dihydroanthracene-2,6-diyl)-
bis(azanediyl)bis(1-oxo-propane-2,1-diyl))bis(4-aminopiperi-
dine-4-carboxamide)-tetra-triﬂuoroacetate (D-4c). We fol-
lowed the synthetic procedures reported for D-4a, starting from
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intermediate 3a and 1-Fmoc-4-(Fmoc-amino)-piperidine-4-
carboxylic acid (Fmoc-Pip(Fmoc)-OH). Yield: 63%. Orange
solid. K′ (HPLC): 4.7. 1H NMR (DMSO-d6, 400 MHz): δ
10.69 (s, 2H), 8.46 (t, 2H), 8.31 (d, 2H), 8.18 (bs, 4H), 8.15
(d, 2H), 8.03 (dd, 2H), 7.90 (bs, 6H), 4.34 (m, 2H), 3.58 (m,
4H), 3.14 (m, 4H), 2.85 (m, 4H), 2.71 (m, 4H), 1.31 (d, 6H).
13C NMR (DMSO-d6, 400 MHz): δ 182.04, 171.37, 169.08,
145.22, 135.00, 129.21, 128.59, 124.19, 116.45, 56.87, 51.23,
35.72, 28.96, 17.94. ESI-MS: 633.4 [M + H]+; 317.2 [M +
2H]++.
N,N′-(2S,2′S)-1,1′-(9,10-Dioxo-9,10-dihydroanthracene-
2,6-diyl)bis(azanediyl)bis(1-oxopropane-2,1-diyl)bis(2,4-dia-
minobutanamide)-tetra-triﬂuoroacetate (D-4d). We followed
the synthetic procedures reported for D-4a, starting from the
intermediate 3c and Fmoc-β-Alanine-OH (Fmoc-β-Ala-OH).
Yield: 81%. Yellow solid. K′ (HPLC): 4.1. 1H NMR (DMSO-
d6, 400 MHz): δ 10.85 (s, 2H), 8.91 (t, 2H), 8.48 (d, 2H), 8.18
(d, 2H), 8.07 (dd, 2H), 7.78 (bs, 6H), 4.54 (m, 2H), 2.82 (m,
4H), 1.75 (m, 4H), 1.38 (d, 6H). 13C NMR (DMSO-d6, 400
MHz): δ 181.99, 171.16, 169.46, 144.96, 134.87, 129.25,
128.61, 124.07, 116.55, 51.33, 36.02, 33.03, 18.13. ESI-MS:
523.5 [M + H]+; 261.2 [M + 2H]++.
N,N′-(2S,2′S)-1,1′-(9,10-dioxo-9,10-dihydroanthracene-
2,6-diyl)bis(azanediyl)-bis(1-oxopropane-2,1-diyl)bis(2,3-dia-
minopropanamide)-tetra-triﬂuoroacetate (D-4e). We fol-
lowed the synthetic procedures reported for D-4a, starting
from intermediate 3a and Nα-Fmoc-Nβ-Boc-L-diaminopro-
pionic acid (Fmoc-Dap(Boc)-OH). Yield: 86%. Orange solid.
K′ (HPLC): 4.8. 1H NMR (DMSO-d6, 400 MHz): δ 10.92 (s,
2H), 9.00 (t, 2H), 8.47 (bs, 6H), 8.19 (bs, 6H), 8.18 (d, 2H),
8.06 (d, 2H), 8.04 (dd, 2H), 4.55 (m, 2H), 4.21 (m, 2H), 3.15
(m, 4H), 1.43 (d, 6H). 13C NMR (DMSO-d6, 400 MHz): δ
181.81, 172.169, 158.77, 144.65, 134.81, 129.07, 128.85,
124.26, 116.61, 50.82, 50.36, 40.15, 18.30. ESI-MS: 553.5 [M
+ H]+; 277.2 [M + 2H]++.
N,N′-(2S,2′S)-1,1′-(9,10-Dioxo-9,10-dihydroanthracene-
2,6-diyl)bis(azanediyl)-bis(1-oxopropane-2,1-diyl)bis(2,4-dia-
minobutanamide)-tetra-triﬂuoroacetate (D-4f). We followed
the synthetic procedures reported for D-4a, starting from
intermediate 3a and Nα-Fmoc-Nγ-Boc-L-diaminobutyric acid
(Fmoc-Dab(Boc)-OH). Yield: 79%. Orange solid. K′ (HPLC):
4.8. 1H NMR (DMSO-d6, 400 MHz): δ 10.81 (s, 2H), 8.87 (t,
2H), 8.45 (bs, 6H), 8.17 (d, 2H), 8.16 (d, 2H), 8.04 (dd, 2H),
7.78 (bs, 6H), 4.53 (m, 2H), 3.82 (m, 2H), 2.84 (m, 4H), 1.75
(m, 4H), 1.41 (d, 6H). 13C NMR (DMSO-d6, 400 MHz): δ
181.88, 172.10, 168.69, 145.33, 134.87, 129.11, 128.73, 124.24,
116.55, 50.86, 50.31, 35.41, 29.48, 18.13. ESI-MS: 581.4 [M +
H]+; 291.3 [M + 2H]++.
N,N′-(1,1′-(9,10-Dioxo-9,10-dihydroanthracene-2,6-diyl)-
bis(azanediyl)bis(1-oxo-propane-2,1-diyl))bis(2,5-diamino-
pentanamide)-tetra-triﬂuoroacetate (D-4g). We followed the
synthetic procedures reported for D-4a, starting from
intermediate 3a and Nα-Fmoc-Nδ-Boc-L-ornithine (Fmoc-
Orn(Boc)-OH). Yield: 81%. Orange solid. K′ (HPLC): 4.8.
1H NMR (DMSO-d6, 400 MHz): δ 10.88 (s, 2H), 8.86 (t, 2H),
8.46 (bs, 6H), 8.18 (d, 2H), 8.16 (d, 2H), 8.06 (dd, 2H), 7.85
(bs, 6H), 4.51 (m, 2H), 3.85 (m, 2H), 3.16 (m, 4H), 2.83 (m,
4H), 1.77 (m, 4H), 1.41 (d, 6H). 13C NMR (DMSO-d6, 400
MHz): δ 181.99, 169.77, 168.13, 144.74, 134.24, 129.09,
128.69, 124.24, 116.49, 52.13, 50.24, 38.84, 28.44, 22.79, 18.18.
ESI-MS: 609.4 [M + H]+; 305.4 [M + 2H]++.
N,N′-(2S,2′S)-1,1′-(9,10-Dioxo-9,10-dihydro-anthracene-
2,6-diyl)bis(azanediyl)-bis(1-oxopropane-2,1-diyl)bis(2,6-dia-
minohexanamide)-tetra-triﬂuoroacetate (D-4h). We fol-
lowed the synthetic procedures reported for D-4a, starting
from intermediate 3a and Nα-Fmoc-Nε-Boc-L-Lysine (Fmoc-
Lys(Boc)-OH. Yield: 83%. Orange solid. K′ (HPLC): 4.9. 1H
NMR (DMSO-d6, 400 MHz): δ 10.86 (s, 2H), 8.86 (t, 2H),
8.44 (bs, 6H), 8.18 (d, 2H), 8.16 (d, 2H), 8.06 (dd, 2H), 7.78
(bs, 6H), 4.50 (q, 2H), 3.85 (m, 2H), 2.75 (m, 4H), 1.72 (m,
4H), 1.54 (m, 4H), 1.40 (d, 6H), 1.33 (m, 4H). 13C NMR
(DMSO-d6, 400 MHz): δ 181.87, 172.19, 168.90, 158.75,
144.93, 134.84, 129.09, 128.67, 124.08, 116.44, 52.22, 50.04,
38.97, 30.88, 26.93, 21.48, 18.12. ESI-MS: 636.9 [M + H]+;
319.1 [M + 2H]++.
N,N′-(2S,2′S)-1,1′-(9,10-Dioxo-9,10-dihydroanthracene-
2,6-diyl)bis(azanediyl)bis(1-oxopropane-2,1-diyl)bis(2-
am ino - 3 - ( 4 - am inopheny l ) p r opanam ide ) - t e t r a -
triﬂuoroacetate(D-4i). We followed the synthetic procedures
reported for D-4a, starting from intermediate 3a and Fmoc-4-
(Boc-amino)-L-phenylalanine (Fmoc-4-(NH-Boc)Phe-OH).
Yield: 69%. Orange solid. K′ (HPLC): 5.1. 1H NMR
(DMSO-d6, 400 MHz): δ 10.74 (s, 2H), 8.74 (t, 2H), 8.44
(bs, 6H), 8.18 (d, 2H), 8.15 (d, 2H), 8.02 (dd, 2H), 7.01 (d,
4H), 6.94 (d, 4H), 6.72 (bs, 6H), 4.44 (m, 2H), 4.00 (m, 2H),
2.88 (m, 4H), 1.22 (d, 6H). 13C NMR (DMSO-d6, 400 MHz):
δ 182.05, 169.72, 168.36, 158.32, 144.45, 134.95, 130.94,
129.03, 128.84, 128.58, 123.93, 118.84, 116.52, 53.93, 50.31,
36.87, 18.03. ESI-MS: 705.2 [M + H]+; 353.1 [M + 2H]++.
Inhibition of NC-Mediated Destabilization of TAR and
cTAR Stem. The identiﬁcation of inhibitors able to impair the
NC chaperone activity on TAR and cTAR was performed by
means of the high throughput screening (HTS) previously
described.13,14,16
Inhibition of NC-Mediated TAR/cTAR Annealing. We
investigated the ability of the newly synthesized 2,6-AQ-D-Ala-
X anthraquinones to impair the annealing activity of full-length
NC protein activity monitoring the annealing of TAR with
cTAR through the nucleocapsid annealing mediated electro-
phoresis (NAME) assay described earlier,12,18 which was
carried out according to alternative protocols involving
preincubation of ligand with either the NC protein or the
nucleic acid substrates.12 Selected compounds were further
analyzed using diﬀerent sets of concentrations in the oligo-
preincubation mode to accurately determine their potency in
inhibiting NC-mediated annealing activity.13
Direct Binding of Ligands to Individual TAR and cTAR.
We evaluated the binding properties of selected 2,6-AQ-D-Ala-
X anthraquinones to either TAR or cTAR employing
electrospray ionization mass spectrometry (ESI-MS) analysis
under nondenaturing conditions as previously reported for the
L-Ala series.12,13,19−21 The determination of free and bound
RNA or DNA, necessary to evaluate the binding aﬃnity of
compounds to TAR and cTAR, was assessed from the relative
abundances, expressed as percentage and compared.24 The
binding properties of selected compounds were evaluated also
toward the stem-loop SL3 and the double-stranded RNA. SL3
construct was heated to 95 °C for 5 min and then ice-cooled in
order to assume the proper hairpin structure. The dsRNA was
also heated and then slowly cool to room temperature in order
to form the RNA duplex. ESI-MS experiments were performed
under the same experimental conditions used in the presence of
TAR.
Direct Binding of Ligands to NC. The direct binding of
selected 2,6-AQ-D-Ala-X anthraquinones to the full-length NC
protein was assessed by ESI-MS in positive ion mode via direct
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infusion nanospray ionization on a Synapt G2 HDMS traveling-
wave ion mobility spectrometry (IMS) mass spectrometer
(Waters, Manchester, UK).50 Typical ﬁnal mixtures contained
up to 10:1 2,6-dipeptidyl-anthraquinone:NC molar ratio in 150
mM ammonium acetate (pH 7.5). Mass Lynx (v 4.1, SCN781)
software was used to process data. To evaluate the binding
aﬃnity of compounds to the full-length NC, free and
complexed protein abundances in each experiment were
calculated as reported earlier for TAR and cTAR, and were
ﬁnally expressed as percentage and compared.
Inhibition of NC Binding to TAR. Possible eﬀects induced
by 2,6-dipeptidyl anthraquinones on the speciﬁc binding of NC
protein to TAR substrate were evaluated by analyzing samples
in which preformed i, NC-TAR; ii, ligand-NC; or iii, ligand-
TAR complexes were challenged by addition of the remaining
component as exempliﬁed in Scheme 3. With the concentration
of each component kept constant in the three diﬀerent
procedures, only the order of incubation changed to evaluate
all the possible scenarios. Samples were prepared by incubating
equimolar amounts of NC and TAR (i.e., 6 μM concentration
of each) and a 1:10 molar ratio of each ligand (i.e., ﬁnal 60 μM
concentration) in 150 mM ammonium acetate (pH 7.5). ESI-
MS performed under nondenaturing conditions was applied to
unambiguously identify all species present at equilibrium in
solution. In order to characterize all the reaction products, all
samples were analyzed in both positive and negative ion modes
via direct infusion nanospray ionization on a Synapt G2 HDMS
traveling-wave ion mobility spectrometry (IMS) mass spec-
trometer (Waters, Manchester, UK), using the same conditions
used for the binding analysis of ligands to NC. Data were
processed by using Mass Lynx (v 4.1, SCN781) software. To
evaluate the binding of the full-length NC to TAR construct,
free and complexed protein abundances in each experiment
were calculated, expressed as percentage and compared.
Inhibition of Tat/TAR Complex Formation. The eﬀect of
anthraquinone derivatives on the Tat/TAR complex was
evaluated using a FRET-based competition assay, as previously
described.14,33,51
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